Federal Schedule III Reclassification Unlocks Tax Relief, Capital for U.S. Cannabis
Department of Justice reclassified cannabis to Schedule III under the Controlled Substances Act, enabling MSOS to benefit from relief from punitive 280E tax treatment. This shift expands research access, institutional capital participation and banking services for U.S. cannabis operators employing over 400,000 Americans.
1. DOJ Finalizes Schedule III Rescheduling
On April 23, 2026 the Department of Justice reclassified cannabis to Schedule III under the Controlled Substances Act, moving it out of a policy gray area and into a defined regulatory framework that applies to other Schedule III substances.
2. Tax Relief and Research Expansion
The Schedule III designation removes the punitive Section 280E tax treatment for cannabis businesses, paving the way for improved after-tax profitability and expanded licensing for clinical and scientific research.
3. Institutional Participation and Banking Access
Rescheduling clears a critical barrier to institutional capital, allowing professional investors and fund managers to allocate to cannabis equities and enabling operators to secure traditional banking services, loans and mortgages.
4. Implications for MSOS
AdvisorShares Pure US Cannabis ETF, which holds leading multi-state operators, stands to see enhanced fund flows and valuation support as tax burdens ease, research opportunities grow and institutional participation accelerates.